Zhejiang Shapuaisi Pharmaceutical (603168.SH): Olodaterol hydrochloride eye drops obtained drug registration certificate
Shapuaisi (603168.SH) announced that the company has received approval from the National Medical Products Administration for the issuance of hydrochloride...
Zhejiang Shapuaisi Pharmaceutical (603168.SH) announced that the company has received the Drug Registration Certificate for Olopatadine Hydrochloride Eye Drops approved and issued by the National Medical Products Administration. The approved Olopatadine Hydrochloride Eye Drops are used to treat eye itching related to allergic conjunctivitis.
Related Articles
Brokerage Morning Meeting Highlights | Suggestions for the Consumer Sector: Focus on the Rise of Domestic Brands, Structural Opportunities such as AI + Consumption.
HBM HOLDINGS-B(02142) signs global strategic cooperation and licensing agreement with Bayer Pharmaceutical Company.
HUTCHMED (00013) initiates global clinical development of the ATTC candidate drug HMPL-A251 for the treatment of solid tumors.
Brokerage Morning Meeting Highlights | Suggestions for the Consumer Sector: Focus on the Rise of Domestic Brands, Structural Opportunities such as AI + Consumption.
HBM HOLDINGS-B(02142) signs global strategic cooperation and licensing agreement with Bayer Pharmaceutical Company.
HUTCHMED (00013) initiates global clinical development of the ATTC candidate drug HMPL-A251 for the treatment of solid tumors.
RECOMMEND
Super Central Bank Week Arrives! Japan Leads With A Rate Hike As Developed Economies End The Rate‑Cut Cycle, Will The Fed Cut Alone Next Year?
16/12/2025
What Guidance Does The Economic Work Conference Offer For Cross‑Year Market Direction?
16/12/2025
Trade Surplus Tops One Trillion USD: New Challenges For China’s Foreign Trade | Instant Commentary
16/12/2025
